Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Cel-Sci Corp. (CVM) Starts Presentation at the 2012 Aegis Healthcare Conference

Cel-Sci is focused on the research and development of improvements in the treatment of cancer and other diseases by utilizing the body’s immune system. Its lead investigational therapy, Multikine, is currently being studied in a pivotal global phase 3 clinical trial. The company is also developing an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine for Rheumatoid Arthritis using its LEAPS technology platform. The LEAPS drug candidates are currently in preclinical testing. For more information visit the company’s Web site at: www.cel-sci.com.

Aegis Capital Corp. is a full service retail and institutional broker-dealer located in New York City. Aegis Capital’s management is committed to providing the highest level of service to its clients. The firm realizes this goal by running an independent, conflict-free platform that is focused on enhancing the goals of clients by bringing unencumbered advice, which enables them to freely create a plan centered on each client. For more information on Aegis Capital, visit www.aegiscapcorp.com.

Let us hear your thoughts below:

This entry was posted in Aegis Conference. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *